(lp0
S"Court Victory Benefits Biogen And Its Tecfidera Rival Alike Seeking Alpha - 11 hours ago Biogen's  win against the hedge fund manager Kyle Bass should, subject to appeal, secure its multiple sclerosis blockbuster Tecfidera until 2028.Biogen wins patent ruling for its $4 billion MS treatment - The Boston GlobeBiogen prevails in dispute over key Tecfidera patent - Boston Business Journal"
p1
aS"Biogen Inc: MS drug patent ruling win clears uncertainty Times of India - Mar 21, 2017 U.S. patent office says key patent on Biogen's top-seller and market-leading oral multiple sclerosis  treatment, Tecfidera, protect drug until at least 2026 and beyond."
p2
aS"Taking a Fresh Look at Biogen Inc.  StockNewsJournal - 13 hours ago Biogen Inc.  is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $275.79, up from yesterday's close by 0.36%.Mizuho Reaffirms Neutral Rating for Biogen Inc  - Sports PerspectivesPutnam Investments LLC Has $229854000 Position in Biogen Inc  - The Cerbat Gem"
p3
aS"Biogen Inc.  Pulled Back Sharply After Downgrade RTT News - Mar 17, 2017 Morgan Stanley downgraded its rating on shares of Biogen Inc.  Thursday morning to &quot;Equal weight&quot; from &quot;Overweight.Why Guess?, Inc. , Biogen Inc  and Snap Inc  Are 3 of Today's ... - Investorplace.comMorgan Stanley Takes A Breather On Biogen, Downgrades Stock - Benzinga"
p4
aS'Biogen Inc.  Moves Higher on Volume Spike for March 21 Equities.com - Mar 21, 2017 Biogen Inc.  traded on unusually high volume on Mar. 21, as the stock gained 0.36% to close at $275.79. On the day, Biogen Inc. saw 3.82 million shares trade hands on 38,946 trades. Considering that the stock averages only a daily volume of 1.65&nbsp;...'
p5
aS'Did Biogen Inc. Shoot Itself in the Foot? Motley Fool - Feb 21, 2017 Spinraza, the second drug to earn FDA approval from Ionis Pharmaceuticals  is a potential life-saver, but the enormous list price set by its marketing partner, Biogen , received icy responses from some big American health&nbsp;...'
p6
aS"Better Buy: Biogen Inc. vs. Gilead Sciences Inc. Motley Fool - Feb 27, 2017 Biogen  and Gilead Sciences  don't compete against each other -- at least not yet. Both biotechs are interested in the oncology and autoimmune disease therapeutic areas, so there's always a chance they could become rivals."
p7
aS'Biogen Inc.  shares to see major resistance at $282.15 USA Commerce Daily - 12 hours ago With all other things going on, Biogen Inc.  has been on a free fall - declining -3.7 percent in just three months.'
p8
aS'Biogen Inc.  Is Making A Strong Argument Through Its Technicals NY Stock News - 11 hours ago The technicals for Biogen Inc.  has spoken via its technical chart and the message is loud and clear. Based on that message, this is the relevant information necessary to make sense of that current setup.'
p9
aS'Today Analysts Focus on Biogen Inc. , Fidelity National Information ... StockNewsJournal - Mar 21, 2017 Biogen Inc.  have shown a high EPS growth of 27.40% in the last 5 years and has earnings decline of 10.30% yoy. Analysts have a mean recommendation of 2.20 on this stock (A rating of less than 2 means buy, hold within the 3 range, sell within ...'
p10
a.